Dr. Ronald D. Emkey, M.D., F.A.C.P., FACR
Following an internal medicine residency, Dr. Emkey completed a rheumatology/metabolic bone disease fellowship at the Massachusetts General Hospital, Harvard Medical School, during which his career in bone research was initiated. Dr. Emkey's initial interests were in the field of cellular biology and the effects of various prostaglandins on the resorption of bone, both in osteoporosis and rheumatoid arthritis. He was involved in the pivotal early phase clinical trials on bisphosphonates, calcitonin, parathyroid hormone, and denosumab. He participated in research leading to the release of all the current treatments for osteoporosis and served as a consultant in the development of new medications involving the treatment of osteoporosis and rheumatoid arthritis. He has participated in more than 250 research studies, primarily in the field of osteoporosis and rheumatoid arthritis. He has published over 135 manuscripts and abstracts and has presented research at several international meetings. His publications have appeared in most of the leading journals, including two lead articles in The New England Journal of Medicine, The Annals of Internal Medicine, The American Journal of Medicine, and in several subspecialty journals, including The Journal of Bone Mineral Research, Osteoporosis International, Bone and additional articles in clinical therapeutics. He served as chairman of the rheumatology section at The Reading Hospital and Medical Center for 28 years and developed a Bone Research Center at The Reading Hospital and Medical Center and served as its director. Dr. Emkey currently maintains an active rheumatology practice with teaching responsibilities and serves as a consultant and on advisory boards in the development of new medications in addition to serving as Director, Metabolic Bone Diseases, Pennsylvania Regional Center for Arthritis and Osteoporosis Research, Wyomissing, PA.